Study for the Clinical Roadmap and Prognosis of Pulmonary Artery Sarcoma.

Last updated: December 11, 2023
Sponsor: China-Japan Friendship Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Sarcoma

Treatment

N/A

Clinical Study ID

NCT06165718
Roadmap for PAS-2022
  • All Genders

Study Summary

This is an observational study in which patients with pulmonary artery sarcoma were followed up for at least 36 months and survival was investigated.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Computed tomography pulmonary angiography indicated that there were intraluminaldefects
  • Malignant histopathology was sarcoma
  • Informed consent form was signed

Exclusion

Exclusion Criteria:

  • Life expectancy was less than 3 months due to diseases other than pulmonary arterysarcoma
  • Expected inability to complete follow-up

Study Design

Total Participants: 120
Study Start date:
December 31, 2022
Estimated Completion Date:
June 30, 2025

Study Description

This is an observational study covering mainland China, and patients with pulmonary artery sarcoma were followed up for at least 36 months and survival was investigated.

Connect with a study center

  • China-Japan Friendship Hospital

    Beijing, Beijing 100029
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.